Search clinical trials for: GI-101A

Total 1154 results

Healthpoint

Withdrawn

HP011-101, HP828-101, and Standard Care for Pressure Ulcers

Pressure Ulcers
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
Alaunos Therapeutics

Unknown

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Advanced Solid Tumors | Lymphomas

Canada
Akili Interactive Labs, Inc.
Landmark College; Villa Maria College

Recruiting

EndeavorOTC® Research Study in College Students

Cognition | Attention | University Students

United States
Mylan Specialty, LP

Completed

Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.

Pain | Acute Pain | Post Operative Pain

United States
John Villano

Withdrawn

NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer

Small Cell Lung Cancer | Brain Metastasis

United States
Mylan Inc.

Completed

Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain

Pain | Postoperative Pain | Pain, Acute

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Germany
BlueWillow Biologics
Porton Biopharma Ltd.

Completed

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults (IN NE-rPA)

Anthrax

United States
Centers for Disease Control and Prevention
Procter and Gamble; The New York Center for Travel and Tropical Medicine

Terminated

Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

Antibiotic Resistant Infection | Diarrhea Travelers

United States
University Hospital of North Norway

Completed

Distribution of FMT After Delivery by · Lower GI Endoscopy vs Enema With and Without Positioning of the Patient

Fecal Microbiota Transplantation

Norway
Axovant Sciences Ltd.

Completed

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

Dementia With Lewy Bodies

United States, Canada, France, Italy, Netherlands, Spain, United Kingdom
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Boehringer Ingelheim

Completed

Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects

Healthy
Ralexar Therapeutics, Inc.

Unknown

Study in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis Eczema

United States, Canada
Axovant Sciences Ltd.

Terminated

Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

Dementia With Lewy Bodies

United States, Canada, France, Italy, Netherlands, Spain, United Kingdom
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Colorectal Cancer Metastatic | mCRC

United States
InQpharm Group

Completed

Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

Postprandial Heartburn

Germany
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
Athira Pharma
Alturas Analytics, Inc.; Labcorp Drug Development Inc

Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

Healthy Volunteers

United States
Hookipa Biotech GmbH
Centre for Vaccinology Ghent - CEVAC

Completed

Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

Cytomegalovirus Infection

Belgium
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

Healthy

Germany
Leiden University Medical Center

Recruiting

SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia (SGM-T1)

Colorectal Cancer | Image | Low Grade Dysplasia of Colon

Netherlands
CellinCells

Recruiting

Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

Atrophic Scar

Korea, Republic of
Perceive Biotherapeutics, Inc.

Recruiting

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

Australia, Israel
Isotech Ltd
Newcastle-upon-Tyne Hospitals NHS Trust

Recruiting

A Novel Device for the Treatment of Postural Hypotension - a Signal of Effectiveness Study.

Orthostatic Hypotension

United Kingdom
AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Hematologic Cancer

United States, Israel, Japan
Antengene (Hangzhou) Biologics Co., Ltd.

Recruiting

A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

China
Neurogene Inc.

Recruiting

Gene Therapy Study for Children With CLN5 Batten Disease (CLN5-200)

Neuronal Ceroid Lipofuscinosis CLN5

United States, United Kingdom
Heidelberg Pharma AG

Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Multiple Myeloma | Plasma Cell Disorder

United States, Germany, Poland, Hungary
Excision BioTherapeutics

Enrolling by invitation

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

HIV-1-infection

United States
CorrectSequence Therapeutics Co., Ltd
First Affiliated Hospital of Guangxi Medical University

Enrolling by invitation

CS-101 in Patients With β-thalassemia

Beta-Thalassemia

China
Tvardi Therapeutics, Incorporated
M.D. Anderson Cancer Center

Active, not recruiting

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Melanoma | Breast Cancer | Colorectal Cancer | Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Cancer | Head and Neck Squamous Cell Carcinoma | Hepatocellular Cancer

United States
Verve Therapeutics, Inc.

Active, not recruiting

A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | Heterozygous Familial Hypercholesterolemia

New Zealand, United Kingdom
Auris Medical AG

Completed

AM-101 in the Treatment of Post-Acute Tinnitus 2 (AMPACT2)

Tinnitus

Germany
Engrail Therapeutics INC

Withdrawn

ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures (ENACT)

Focal Epilepsy

United States
Auris Medical, Inc.

Completed

AM-101 in the Treatment of Post-Acute Tinnitus 1 (AMPACT1)

Tinnitus

United States
Curis, Inc.

Completed

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

Tumors

United States
Aldagen

Terminated

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases (UCBT-002)

Mucopolysaccharidosis | Inborn Errors of Metabolism | Lysosomal Storage Disorders | Inherited Metabolic Diseases | Peroxisomal Storage Diseases

United States
Auris Medical AG

Completed

Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus

Tinnitus

Germany
University of Michigan

Completed

Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging

Myocardial Infarction | Ischemic Heart Disease

United States
Bioray Laboratories
Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of...

Not yet recruiting

Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

Sickle Cell Disease
Aclaris Therapeutics, Inc.

Completed

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis

United States
Emerald Health Pharmaceuticals

Suspended

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis

United States, Australia
Euthymics BioScience, Inc.

Completed

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Major Depressive Disorder

United States
Scioderm, Inc.
Amicus Therapeutics

Completed

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

Italy, Spain, Serbia, United States, Australia, Netherlands, Austria, Germany, Israel, Lithuania, France, United Kingdom, Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Kythera Biopharmaceuticals

Completed

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

Healthy

United States
Tianjin ConjuStar Biologics Co., Ltd.

Recruiting

Study SC-101 in Subjects With Advanced Malignancies

Advanced Solid Tumor

China

Search clinical trials for: GI-101A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations